|
| 36595210 | Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis. | | 2023 |
| 37738717 | Sequential management of postmenopausal health and osteoporosis: An update. | | 2023 |
| 37582396 | Using advanced analytics to help identify women who are more likely to have a severe subjective experience of vulvovaginal atrophy: a modeling study. | | 2023 |
| 37553099 | Response to Letter to the Editor on "A randomized trial on the effectiveness and safety of 5 water-based personal lubricants". | | 2023 |
| 37084589 | Oral estradiol/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens/medroxyprogesterone acetate in real-world practice. | | 2023 |
| 37029724 | Miconazole for the treatment of vulvovaginal candidiasis. , and clinical results. Review of the literature. | | 2023 |
| 37017751 | Expert opinion on the treatment of vulvovaginal atrophy with ospemifene based on new evidence. | | 2023 |
| 37105219 | Sequential treatment in vulvovaginal atrophy. | | 2023 |
| 37099983 | Impact of vulvovaginal atrophy therapies on postmenopausal women's quality of life in the CRETA study measured by the Cervantes scale. | | 2023 |
| 36724207 | The drospirenone (DRSP)-only pill: clinical implications in the daily use. | | 2023 |
| 36781402 | A randomized trial on the effectiveness and safety of 5 water-based personal lubricants. | | 2023 |
| 34931570 | Strategy to improve the female fertility in the general gynecologist's office: use of a nutritional supplement based on myo-inositol/D-chiro-inositol and antioxidants. | Gynecological Endocrinology | 2022 |
| 36081216 | Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group. | | 2022 |
| 36331798 | Novel formulations of oral bisphosphonates in the treatment of osteoporosis. | Aging clinical and experimental research | 2022 |
| 35670533 | Long-term use of ospemifene in clinical practice for vulvo-vaginal atrophy: end results at 12 months of follow-up. | Gynecological Endocrinology | 2022 |
| 36425899 | Current situation of shared decision making in osteoporosis: A comprehensive literature review of patient decision aids and decision drivers. | Health Science Reports | 2022 |
| 36599366 | Obesity in women's life: role of GLP-1 agonists. | | 2022 |
| 34463164 | Vaginal health, endometrial thickness and changes in bone markers in postmenopausal women after 6 months of treatment with ospemifene in real clinical practice. | Gynecological Endocrinology | 2022 |
| 35261299 | Bleeding profile of women with cardiovascular risk factors using a drospirenone only pill with 4â¿¿mg over nine cycles compared to desogestrel 0.075â¿¿mg. | Gynecological Endocrinology | 2022 |
| 34382489 | Medical treatment of osteoporosis. | Climacteric | 2022 |
| 34490504 | Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis. | Osteoporosis International | 2022 |
| 34813408 | Efficacy of low-dose vaginal 17β-estradiol versus vaginal promestriene for vulvovaginal atrophy. | Climacteric | 2022 |
| 34402728 | Overall and bleeding-related discontinuation rates of a new oral contraceptive containing 4â¿¿mg drospirenone only in a 24/4 regimen and comparison to 0.075â¿¿mg desogestrel. | Gynecological Endocrinology | 2021 |
| 33746195 | Efficacy of a Coriolus versicolor-Based Vaginal Gel in Women With Human Papillomavirus-Dependent Cervical Lesions: The PALOMA Study. | Journal of Lower Genital Tract Disease | 2021 |
| 34010936 | Prevalence and impact on quality of life of vasomotor symptoms. | Menopause | 2021 |
| 33722362 | Population-based norms for the Cervantes-SF short-form questionnaire assessing health-related quality of life in menopause. | | 2021 |
| 34348526 | Metabolic and laboratory effects of a progestin-only pill containing drospirenone 4⿿mg in comparison to desogestrel 75 µg: a double-blind, double-dummy, prospective, randomised study. | European Journal of Contraception and Reproductive Health Care | 2021 |
| 32869682 | Vaginal Health: Insights, Views & Attitudes survey in Latin America (VIVA-LATAM): focus on Brazil. | Climacteric | 2021 |
| 33300371 | Ospemifene in clinical practice for vulvo-vaginal atrophy: results at 3 months of follow-up of use. | Gynecological Endocrinology | 2021 |
| 32856973 | The European Vulvovaginal Epidemiological Survey (EVES). Impact of history of breast cancer on prevalence, symptoms, sexual function and quality of life related to vulvovaginal atrophy. | Gynecological Endocrinology | 2021 |
| 33345650 | Vitamin D supplementation: position Statement of the Iberoamerican Society of Osteoporosis and Mineral Metabolism (SIBOMM). | Gynecological Endocrinology | 2021 |
| 31387514 | Therapies for the management of genitourinary syndrome of menopause. | Post Reproductive Health | 2020 |
| 31747785 | Efficacy and safety of ossein-hydroxyapatite complex versus calcium carbonate to prevent bone loss. | Climacteric | 2020 |
| 32019391 | Purified and specific cytoplasmic pollen extract: a non-hormonal alternative for the treatment of menopausal symptoms. | Gynecological Endocrinology | 2020 |
| 32068686 | The European Vulvovaginal Epidemiological Survey (EVES): impact on sexual function of vulvovaginal atrophy of menopause. | Menopause | 2020 |
| 32362931 | Clinical study of the tolerability of calcium carbonate-casein microcapsules as a dietary supplement in a group of postmenopausal women. | Drugs in Context | 2020 |
| 32005419 | Evaluation of Femaxeen® for control of urinary incontinence in women: A randomized, double-blind, placebo-controlled study. | | 2020 |
| 31778906 | Efficacy of the use of fractional CO2RE intima laser treatment in stress and mixed urinary incontinence. | European Journal of Obstetrics, Gynecology and Reproductive Biology | 2020 |
| 32328709 | Correction to: A multicenter, double-blind, randomized trial on the bleeding profle of a drospirenone-only pill 4Â mg over nine cycles in comparison with desogestrel 0.075Â mg. | Archives of Gynecology and Obstetrics | 2020 |
| 33208633 | Validity of the Fitzpatrick Skin Phototype Classification in Ecuador. | Advances in Skin and Wound Care | 2020 |
| 32598387 | Bleeding profile of women using a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg. | PLoS ONE | 2020 |
| 32873079 | Non-hormonal approaches for the treatment of vulvovaginal atrophy: the choice between hyaluronic acid and glycerin. | Gynecological Endocrinology | 2020 |
| 33008401 | Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4â¿¿mg drospirenone alone in a 24/4 regime. | BMC Women's Health | 2020 |
| 32670383 | Experience with ospemifene in patients with vulvar and vaginal atrophy: case studies with bone marker profiles. | Drugs in Context | 2020 |
| 32670381 | Experience with ospemifene in patients with vulvar and vaginal atrophy and urinary incontinence: case studies. | Drugs in Context | 2020 |
| 32670380 | Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies. | Drugs in Context | 2020 |
| 32670378 | Ospemifene for vulvar and vaginal atrophy: an overview. | Drugs in Context | 2020 |
| 33110052 | Expression of androgen receptors in the structures of vulvovaginal tissue. | Menopause | 2020 |
| 33109125 | Actinic keratoses in subjects from la Mitad del Mundo, Ecuador. | BMC Dermatology | 2020 |
| 31097180 | Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. | | 2019 |